Kaipharm
Kaipharm helps drug developers identify and reposition compounds using AI-trained models and large drug-induced transcriptome datasets. It combines a proprietary integrated database of compound structures, drug–target and drug–disease relationships, and large-scale drug-induced gene-expression profiles (KMAP) with machine learning-based virtual screening algorithms. Core technologies include next-generation sequencing (NGS) for transcriptome generation, big-data analytics, and two patented algorithms (BEAR and BACoN) for bioactivity-driven virtual screening. Kaipharm operates as a B2B service provider to pharmaceutical and biotech companies, offering in-house data, predictive models, and computational screening workflows. Its platform is positioned to support preclinical discovery and drug-repositioning efforts at scale.
Kaipharm
Kaipharm helps drug developers identify and reposition compounds using AI-trained models and large drug-induced transcriptome datasets. It combines a proprietary integrated database of compound structures, drug–target and drug–disease relationships, and large-scale drug-induced gene-expression profiles (KMAP) with machine learning-based virtual screening algorithms. Core technologies include next-generation sequencing (NGS) for transcriptome generation, big-data analytics, and two patented algorithms (BEAR and BACoN) for bioactivity-driven virtual screening. Kaipharm operates as a B2B service provider to pharmaceutical and biotech companies, offering in-house data, predictive models, and computational screening workflows. Its platform is positioned to support preclinical discovery and drug-repositioning efforts at scale.